EZH2 and cancer: However, the discovery of EZH2 inhibitors and BRD9 inhibitors as possible therapeutic approaches for some cancers with BAF subunit mutations, illustrates why the comprehension of the precise mechanism by which subunit mutations result in tumour growth, is so important.